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The dedicated secretion system ESX-1 of Mycobacterium tuberculosis encoded by the extended RD1 region
(extRD1) assures export of the ESAT-6 protein and its partner, the 10-kDa culture filtrate protein CFP-10, and
is missing from the vaccine strains M. bovis BCG and M. microti. Here, we systematically investigated the
involvement of each individual ESX-1 gene in the secretion of both antigens, specific immunogenicity, and
virulence. ESX-1-complemented BCG and M. microti strains were more efficiently engulfed by bone-marrow-
derived macrophages than controls, and this may account for the enhanced in vivo growth of ESX-1-carrying
strains. Inactivation of gene pe35 (Rv3872) impaired expression of CFP-10 and ESAT-6, suggesting a role in
regulation. Genes Rv3868, Rv3869, Rv3870, Rv3871, and Rv3877 encoding an ATP-dependent chaperone and
translocon were essential for secretion of ESAT-6 and CFP-10 in contrast to ppe68 Rv3873 and Rv3876, whose
inactivation did not impair secretion of ESAT-6. A strict correlation was found between ESAT-6 export and the
generation of ESAT-6 specific T-cell responses in mice. Furthermore, ESAT-6 secretion and specific immuno-
genicity were almost always correlated with enhanced virulence in the SCID mouse model. Only loss of Rv3865
and part of Rv3866 did not affect ESAT-6 secretion or immunogenicity but led to attenuation. This suggests
that Rv3865/66 represent a new virulence factor that is independent from ESAT-6 secretion. The present study
has allowed us to identify new aspects of the extRD1 region of M. tuberculosis and to explore its role in the
pathogenesis of tuberculosis.
Secreted proteins of Mycobacterium tuberculosis have long
been known to be a rich source of immunogens (39), but for
many of them the molecular basis of their export is still poorly
understood. It is well established that proteins containing typ-
ical signal sequences, such as the highly immunogenic T-cell
antigens 85A, 85B, and 85C are secreted by the SecA1 medi-
ated general secretory pathway (33, 44). The analysis of the
genome sequence of M. tuberculosis H37Rv (13) revealed the
presence of a second SecA-like protein, SecA2. This protein
was shown to be involved in the secretion of superoxide
dismutase SodA, an enzyme that is implicated in the oxida-
tive stress response and lacks a signal sequence (5). In
addition, export of some proteins is likely to occur via the
twin-arginine translocation (TAT) system, as genes encod-
ing proteins with putative TAT-specific signal sequences
were identified in the M. tuberculosis genome (10). Small,
highly immunogenic proteins that lack classical signal se-
quences can also be found in mycobacterial culture filtrate.
Many of these proteins belong to the 23-membered Esx
family (43). Among them, the 6-kDa early secreted antigenic
target ESAT-6 (39) and the 10-kDa culture filtrate protein
CFP-10 (4) are both encoded by the region of difference 1
(RD1).
Comparative genomics of the M. tuberculosis complex re-
vealed that overlapping portions of RD1 are absent from the
attenuated or avirulent strains Mycobacterium bovis BCG
(BCG) (3, 22, 28), Mycobacterium microti (7), and the Dassie
bacillus (31) but are present in all fully virulent isolates (12).
Complementation of BCG and M. microti with RD1, using
integrating cosmid pRD1-2F9, resulted in increased virulence
in mice (8, 34) (29), and deletion of RD1 from M. tuberculosis
leads to attenuation of the strain (24, 27). Genetic approaches
coupled to biochemical analyses showed that proteins encoded
by the RD1 locus are part of a secretion system required for
both ESAT-6 and CFP-10 export (9, 23, 24, 35, 40), hereafter
named ESAT-6 system-1 (ESX-1) (9). However, details of the
elements constituting the ESX-1 secretion system, as well as
the mechanisms by which ESX-1 may affect the host-pathogen
interaction, remain largely unknown. Therefore, in the present
study, BCG and/or M. microti strains, and their RD1 comple-
mented counterparts, were subjected to comparative analyses,
by determining two-dimensional protein patterns; in vitro, ex
vivo, and in vivo growth characteristics; and transcriptional
profiles. Systematic inactivation or deletion of genes on cosmid
pRD1-2F9 and analysis of these constructs in recombinant
BCG and/or M. microti allowed us to determine which genes
were required for ESAT-6 and CFP-10 secretion in addition to
those previously identified. Moreover, these constructs were
used to investigate the influence of ESX-1 and each of its
different components on RD1-mediated, antigen-specific im-
munogenicity and virulence.
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Genetic constructs and mycobacterial strains. Inactivation of genes in cosmid
pRD1-2F9, previously used for the expression and secretion of ESAT-6 by BCG
and M. microti OV254 was accomplished by two approaches. First, pRD1-2F9
was digested with endonucleases SnaBI, AvrII, HpaI, or XbaI that had only one
or two restriction sites in the plasmid. Apramycin cassettes were PCR amplified
with oligonucleotides that contained these restriction sites at the 5 ends, using
pUC-derived plasmids as templates. After digestion and purification, apramycin
cassettes were individually ligated into pRD1-2F9 and then electroporated into
DH10B cells (Invitrogen, Carlsbad, CA), generating constructs that had Rv3870
(SnaBI), Rv3871 (AvrII), ppe68 (HpaI), or Rv3876 (XbaI) inactivated by inser-
tion of a cassette. In addition, AscI was used to excise a fragment spanning from
the 3 end of Rv3868 to the middle of Rv3869, while PmlI was used to excise from
pRD1-2F9 a fragment spanning Rv3878 to Rv3881. Genes for which suitable
restriction sites were not available were inactivated by transposon insertion using
the EZ::TN kan2 in vitro transposition kit (Epicenter, Madison, WI) according
to the manufacturer’s instructions. By this approach, knockout (ko) constructs
were obtained for Rv3864, Rv3867, Rv3868, Rv3869, pe35, and Rv3877. The
EZ::TN kan2 transposon contains a restriction site for Sse8387, which is also
present in the vector backbone of pRD1-2F9 just upstream of rv3860. In selected
clones, digestion with Sse8387, gel purification, and religation allowed us to
remove fragments, which were situated between the Sse8387 site upstream of
Rv3860 and the insertion site of the transposon. Constructs Rv3860-64 and
Rv3860-66 were obtained by this strategy. Finally, to delete selected fragments
from the flanking regions of genes esxB and esxA, a 1.5-kb HpaI/SapI fragment
was subcloned into modified pUC19 (NEB) and subjected to genetic modifica-
tion by using two pairs of oligonucleotides containing selected restriction sites.
Modified 1.5-kb fragments were cloned into HpaI/SapI-cut pRD1-2F9 from
which the original 1.5-kb fragment had been removed. By this approach, partial
or complete CFP-10 or ESAT-6 in-frame deletion mutants were constructed
(esxB, esxA, esxA3-24, esxA76-95, and esxA84-95). Modification of the
1.5-kb fragment was also used for the prom(esxB/A) and ppe68 constructs,
deleting fragments spanning from positions 4352123 to 4352235 and from posi-
tions 4351558 to 4352100, respectively. A similar method was used for constructs
Rv3876, in which the SapI-XbaI fragment in rv3876 was replaced by a small
PCR product containing compatible ends. To clone large RD1 fragments from
M. tuberculosis, we used the single NheI restriction site of vector pYUB412 (2)
to insert NheI-digested fragments according to a previously described cloning
procedure (11). This approach generated construct pNheI-Rv3869-79, contain-
ing an NheI fragment of M. tuberculosis H37Rv that spans region from positions
4343610 to 4360040. XhoI restriction profiles of all of the different constructs
were generated and compared to the original pRD1-2F9 profile for control
purposes, and undigested high concentrated plasmid DNA preparations were
then electroporated into electrocompetent cells of M. tuberculosis H37RvRD1
(a gift from William R. Jacobs, Jr.) (24), BCG, or M. microti OV254 as previously
described (8, 34) by using a Bio-Rad Gene Pulser (Bio-Rad, Munich, Germany).
Hygromycin-resistant colonies appearing after 3 to 4 weeks were analyzed for the
presence of the integrated vector by PCR using primers specific for RD1-en-
coded genes as previously described (7).
RNA extraction, cDNA labeling, and microarray experiments. RNA were
extracted from 50 ml of an exponential-phase broth culture at day 15 after
inoculation with a preculture according to the procedure previously described
(42). RNA quality and quantity were assessed on an Agilent 2100 bioanalyzer by
using the RNA 6000 Nano LabChip Kit. cDNA was labeled by incorporation of
Cy3 or Cy5 dCTP during reverse transcription of RNA (Amersham, Uppsala,
Sweden) and hybridized on whole-genome microarrays supplied by the Bacterial
Microarray Group at St. Georges’s (BG@S [http://www.bugs.sghms.ac.uk]).
Independent sets of data from two RNA samples batches followed by dye swap
labeling were analyzed using GeneSpring software (Silicon Genetics, Redwood
City, CA) as recommended by BG@S. Fully annotated microarray data has
been deposited in BG@Sbase (accession number E-BUGS-31 [http://bugs.sgul
.ac.uk/E-BUGS-31]) and also ArrayExpress (accession number E-BUGS-31).
Radiolabeled cDNA from the M. tuberculosis H37RvRD1::RD1-2F9-pe35 ko
mutant for macroarray experiments was obtained by incorporation of [32P]dCTP
during reverse transcription of RNA. Spotting and hybridization of the arrays
was done as previously described (30).
Macrophage internalization assays. Bone-marrow-derived macrophages were
obtained by seeding 5  104cells bone marrow cells from 8-week-old C57BL/6
mice per well in Dulbecco modified Eagle medium with low glucose (1 g/liter)
and high carbonate (3.7 g/liter) concentrations, supplemented with 10% heat-
inactivated fetal calf serum, 10% L-cell-conditioned medium, and 2 mM L-
glutamine. Culture medium was changed at day 4 and then every 3 days, with
cells being differentiated after 7 days. Activated macrophages were prepared by
incubation with 100 U of gamma interferon (IFN-) and 10 ng of lipopolysac-
charide (LPS) (Sigma, Saint Louis, MO)/ml 24 h prior to infection. Alveolar
epithelial A549 cells (American Type Culture Collection) were cultured in RPMI
1640 supplemented with 10% heat-inactivated fetal calf serum. For internaliza-
tion assays, cells were infected with bacterial suspensions at a multiplicity of
infection of 1:1. After 16 h, cells were washed three times with phosphate-
buffered saline before the addition of fresh culture medium. For the kinetics
study, the number of intracellular bacteria was determined at 4 h, days 3 and 6
after infection by the addition of 0.1% Triton X-100 (Fluka, Buchs, Germany)
and serial fold dilutions of cell lysates on Middlebrook 7H11 medium (BD,
Sparks, MD) supplemented with oleic acid-albumin-dextrose-catalase (OADC).
Biochemical analysis.M. bovis BCG and M. microti OV254 recombinants were
grown in 20 ml of Sauton liquid medium and 0.05% Tween 80 at 37°C for 6 and
14 days, respectively. Cultures were harvested by centrifugation. The culture
filtrate was recovered after filtration through 0.22-m-pore-size filters (MillexR
GP; Millipore, Bedford, MA), followed by concentration using a filter with a
3-kDa cutoff (Centricon; Millipore). The mycobacterial pellet was washed twice
and suspended in Tris 20 mM (pH 7.5) containing protease inhibitors (Complete
EDTA Free; Roche Diagnostics GmbH, Mannheim, Germany). Cells were bro-
ken by shaking with 106-m acid washed-glass beads (Sigma, St. Louis, MO) for
8 min at speed 30 in a Mill Mixer (MM300; Retsch GmbH, Haan, Germany). The
whole-cell lysate consisted of the supernatant fraction recovered after removal of
the debris and centrifugation at 14,000 rpm for 30 min. Alternatively, for further
fractionation, beads and unbroken cells were firstly discarded by a 30-min cen-
trifugation at 5,000 rpm. The resulting supernatant was then subjected to a
45-min centrifugation at 14,000 rpm. The cell wall fraction consisted of the pellet,
and the supernatant was further centrifuged at 65,000 rpm for 90 min on a
TL-100 ultracentrifuge (Beckman, Fullerton, CA). The cytosolic and membrane
fractions correspond to the resulting supernatant and pellet, respectively. Total
protein concentrations were determined by using a Bio-Rad protein assay (Bio-
Rad), and 20-g samples were subjected to sodium dodecyl sulfate-polyacrylam-
ide gel electrophoresis (SDS-PAGE). Immunoblot analysis were carried out with
mouse ESAT-6 monoclonal antibody (Hyb 76-8; Statens Serum Institute, Copen-
hagen, Denmark) and His-tag H-15 (Santa Cruz Biotechnology, Santa Cruz,
CA), CFP-10, and PPE68 rabbit polyclonal antibodies.
Virulence studies and immunological analyses. Mycobacterial strains were
grown and suspensions prepared as described previously (8). Six-week-old male
C.B-17/Icr Ico SCID mice, female C57BL/6 mice (Charles River, St. Germain sur
l’Arbresle, France), tumor necrosis factor alpha (TNF-) ko mice (B6;129-LT-
/TNF- tm1; CDTA, Orle´ans, France), IFN- receptor ko mice (inbred 129/Sv
mice obtained from Michel Aguet [25] by Jean-Franc¸ois Bureau [Institut Pas-
teur, Paris, France] and bred at Pasteur Institute Facility since 1993) were
infected intravenously (106 CFU). Organs from sacrificed mice were homoge-
nized by using an MM300 (QIAGEN, Hilden, Germany) apparatus and 2.5-mm-
diameter glass beads. Serial fivefold dilutions in medium were plated on 7H11
agar with 50 g of hygromycin ml1 when appropriate, and the CFU count was
ascertained after 4 weeks of growth at 37°C for M. microti recombinant strains
and 3 weeks for recombinant BCG.
For immunological studies, adult C57BL/6 (H-2b) mice were injected subcu-
taneously with 106 CFU of recombinant M. microti and BCG recombinant
strains. At 3 weeks postimmunization, splenocytes were cultured (106 cells/well),
and IFN- production was assessed with 10 g of purified protein derivatives
(Statens Serum Institute)/ml; 4 g of recombinant ESAT-6, CFP-10, or MalE/ml;
or 10 g of synthetic peptides (kindly provided by Marcella Simsova and Peter
Sebo)/ml. After 72 h of incubation, amounts of IFN- were quantified in culture
supernatants with a detection limit of 500 pg/ml as described elsewhere (29).
RESULTS
Expression of RD1 in vitro triggers secretion of proteins
ESAT-6 and CFP-10 but does not affect the bacterial growth
rate and gene transcription. In order to determine the possible
role of ESX-1 proteins on the bacterial phenotype, we studied
the growth rate of RD1-complemented strains in different me-
dia and compared their transcriptional and two-dimensional
protein profiles to those of parental strains. BCG::RD1 refers
to the recombinant BCG strain with pRD1-2F9, spanning
Rv3860 to Rv3884 integrated at attB, whereas BCG::pYUB412
is the control strain harboring the empty cosmid. Monitoring
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the in vitro growth rate of BCG::RD1 and M. microti RD1
showed only minor, statistically insignificant differences rela-
tive to vector control strains (data not shown). We then carried
out a comparative transcriptome analysis. After differential
labeling, RNAs extracted during exponential growth were hy-
bridized to an M. tuberculosis H37Rv whole-genome microar-
ray (42). A ratio of 1.5 or higher between the signal of
BCG::RD1 relative to the signal of BCG::pYUB412 was ob-
tained for all of the genes located on the inserted pRD1-2F9
cosmid, confirming that the integrated genes from the RD1
region were efficiently expressed by the recombinant BCG
strain. Neither upregulation nor downregulation of genes cor-
responding to Rv2462c and Rv2463 adjacent to the attB inte-
gration site was noticed. In addition, the expression profiles of
other genes outside the RD1 region were not substantially
altered, suggesting that the RD1 region does not encode reg-
ulators that affect genes elsewhere. Fully annotated microarray
data are available via the BG@Sbase (see Materials and
Methods).
In parallel, whole-cell extracts and culture filtrate proteins
from exponentially growing BCG::RD1 cultures were analyzed
by two-dimensional gel electrophoresis. ESAT-6 and CFP-10
were present in both fractions, whereas the PPE68 protein was
only found in whole-cell extract of BCG::RD1 as observed
previously (Fig. 1) (16). The amount of secreted ESAT-6 was
found to be ca. 10 ng/108 bacteria, which corresponds to 0.1%
(wt/wt) of total culture filtrate proteins and is 	10-fold greater
than the intracellular form. Western blot analysis with antibod-
ies specific for RD1 antigens revealed that ESAT-6 was
present in isoforms, visible as two spots that differed in their pI
(Fig. 1). The same profiles were obtained for M. microti::RD1
relative to M. microti controls (data not shown). This suggests
that RD1-complemented M. microti and BCG indeed repre-
sent biologically relevant models for studying ESX-1, since two
major spots containing six isoforms of ESAT-6 were also found
for wild-type M. tuberculosis using the same focusing range
from pH 4 to 7 (32). Taken together, our data clearly show that
upon integration of the RD1 region, the ESX-1 antigens are
constitutively expressed and secreted at a high level without
any host selective pressure.
Presence of ESX-1 induced increased uptake of recombi-
nant BCG and M. microti in macrophages. Macrophages are
important sites of growth and dissemination of intracellular
pathogens. Since they represent crucial mediators of innate
immunity, macrophages have been used extensively to analyze
the host-Mycobacterium interactions. To search for the biolog-
ical role of ESX-1 encoded antigens, we examined whether
BCG::RD1 and M. microti::RD1 differed from controls in their
capacity to enter and proliferate within host cells, as recently
suggested by a genome-wide screen of transposon mutants
(36). Murine bone-marrow-derived macrophages were in-
fected overnight with exponentially growing bacteria, and then
the number of CFU in lysed cells was determined. Figure 2A
shows that BCG::RD1 and M. microti::RD1 were engulfed
more efficiently than controls. A similar differential effect was
also observed with bacteria cultured in the presence of Tween
80, which is commonly used to avoid clumping in broth, thus
ruling out the possibility that the higher number of ESX-1-
expressing bacteria inside macrophages is due to the uptake of
bacterial aggregates. The same trend of increased uptake was
noted for M. tuberculosis H37Rv relative to M. tuberculosis
H37Rv-RD1 after 4 h of infection (data not shown). More-
over, such differential uptake was not observed with human
A549 epithelial cell-like cells (data not shown), suggesting that
increased internalization of the RD1-expressing strain was re-
stricted to professional phagocytic cells. Although M. tubercu-
losis was able to multiply in host macrophages, no growth was
observed for the BCG vector control and BCG::RD1 (Fig. 2B).
In addition, in LPS- and IFN--activated macrophages the
growth of recombinant and control strains was comparably
reduced, whereas M. tuberculosis persisted (Fig. 2C). Alto-
gether, these results suggest that ESX-1 proteins may play an
FIG. 1. Two-dimensional analysis of whole-cell extracts (CM) and supernatants (S) of BCG::RD1 and control BCG::pYUB412. Detection was
carried out by silver staining (top) and with monoclonal anti-ESAT-6 and polyclonal anti-CFP-10 and anti-PPE68 antibodies for Western blot
analysis.
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important role for enhanced phagocytosis of ESX-1 containing
tubercle bacilli. This hypothesis is in good agreement with
recently published results of Renshaw et al., who showed that
the ESAT-6–CFP-10 complex specifically binds to the surface
of macrophages (37).
Effect of ESX-1 on interaction of bacteria with the host im-
mune system.To further investigate the interaction of ESX-1 with
the immune system, the influence of RD1-encoded proteins on
bacterial proliferation was evaluated in different mouse models.
We have previously reported that in severe combined immuno-
deficient (SCID) mice, the virulence of BCG increases upon in-
tegration of the ESX-1 system, showing 2- to 3-log-higher bacte-
rial loads in spleens and lungs (34), with mean survival times of
BCG::RD1-infected animals nearing those infected with M. tu-
berculosis (8). The same trend was observed in the present in-
fection study for SCID mice having received BCG::RD1 or
BCG::pYUB412 (Fig. 3A and B). However, in immunocompe-
tent mice (e.g., C57BL/6), intravenous infection with BCG::RD1
did not induce such marked effects, i.e., differential growth was
minor in the spleen but stronger in the lungs compared to the
FIG. 2. (A) Quantification of bacterial uptake (%) at 16 h postin-
fection of murine bone marrow macrophages (BMM
) with BCG and
M. microti expressing the whole RD1 region (RD1) or not () in the
presence or absence of Tween 80. CFU in BMM
 (B) or after acti-
vation with LPS and IFN- (C) at 4 h () and days 3 (u) and 6 (■)
after infection with BCG::pYUB412, BCG::RD1, and M. tuberculosis
H37Rv. Means and standard deviations are from infections done in
quadruplicate wells and are representative of four experiments.
FIG. 3. In vivo bacterial replication of BCG::RD1 in various mouse
models: C57BL/6 wild-type mice (open bars), B6;129-LT-/TNF- ko
mice (light gray bars), inbred 129/Sv IFN- receptor ko mice (dark
gray bars), and SCID mice (black bars). The ratios of CFU counts at
day 28 in spleen (A) and lungs (B) relative to initial dose after intra-
venous infection with 106 CFU are indicated. Each value is the mean
of three or four mice, and the error bars represent standard deviations.
(C) Histological samples of lungs from C57BL/6 wild type (WT),
TNF- ko, and IFN- receptor ko mice, showing compact discrete
lesions in lungs of C57BL/6 mice and large diffuse lesions for TNF-
ko mice infected with BCG::RD1 compared to the absence of lesions
in wild-type and TNF- ko mice infected with the BCG vector control.
Lungs from IFN- receptor ko mice showed lesions with both strains,
although bacterial counts were lower for the vector control. Sections
were stained with hematoxylin and eosin. Magnification, 100.
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control (Fig. 3A and B), suggesting that infection with RD1-
expressing strains can be efficiently controlled by the host immune
system. To better understand the role of the immune system in
the control of bacterial growth in vivo, the effect of ESX-1 on
virulence was further investigated in mice lacking TNF- or im-
paired in IFN- signaling, two key cytokines involved in response
to mycobacterial infection (18, 19, 25). Whereas BCG growth was
not significantly modified by absence of TNF- expression,
BCG::RD1 replicated significantly better in TNF--deficient an-
imals than in wild-type controls (Fig. 3A and B) and induced
extensive lesions in lungs (Fig. 3C). Proliferation of BCG::RD1
was even more enhanced in IFN- receptor-deficient mice, with
CFU numbers 1,000 times higher than those observed in wild-
type controls. Lungs from these mice showed lesions with both
strains, although fewer bacteria were detected for the BCG vector
control (data not shown). These results suggest that immune
responses induced by ESX-1 antigens are generated at both the
innate and adaptive levels to limit mycobacterial replication of
RD1-complemented strains. This finding led us to search for the
key players involved in these processes.
Genes Rv3868 to pe35 but not Rv3864 to Rv3867 are re-
quired for expression and secretion of ESAT-6 and CFP-10. In
order to identify the ESX-1 genes involved in the phenotypic
changes, we constructed a series of modified cosmids, wherein
each gene was inactivated either by insertion of an antibiotic
cassette, by in vitro transposon mutagenesis, or by small deletions
from pRD1-2F9 or pNheI vectors (Fig. 4). These cosmids were
subsequently used to complement M. microti OV254, BCG, or M.
tuberculosisH37RvRD1 (24), a strain which lacks the same RD1
region as BCG. Due to differences in the size of the RD1 dele-
tion, M. microti naturally lacks Rv3864 to Rv3876 and BCG lacks
Rv3871 to Rv3879 (Fig. 4). M. microti was therefore used as host
strain to evaluate the effects of inactivation of rv3864 to rv3870,
whereas the effects of interruption of Rv3871 to Rv3879 were
tested in BCG and/or M. tuberculosis H37RvRD1. Some con-
structs were tested in several strains. The recombinant strains
were first screened for their ability to produce and secrete
ESAT-6 and CFP-10 proteins as monitored by the presence of
these antigens in different fractions. The absence of PPE68 from
culture filtrate was used as an internal control for absence of cell
lysis.
M. microti strains containing variants of pRD1-2F9, lacking
either Rv3860 to Rv3864 or Rv3860 to Rv3866, clearly se-
creted ESAT-6 and CFP-10 (Rv3860-66 [Fig. 5A]). In ad-
FIG. 4. Scheme of the various pRD1-2F9 and pNheI constructs that were integrated into BCG and M. microti. Within the genome shown as
a circle, RD1 refers to the naturally occurring RD1 deletions in M. microti and BCG. For each construct (the name is given above on the left),
the site of the transposon insertion (EZ::TN kan2), apramycin cassette (APRA), or deletion (—) in the corresponding open reading frames relative
to its position in RD1 region is shown. The orientation of the transposon/cassette is shown by the direction of the arrow. pe35, ppe68, esxB, and
esxA correspond to Rv3872, Rv3873, Rv3874, and Rv3875.
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dition, ESAT-6 and CFP-10 export by recombinant M. mi-
croti also occurred from transposon mutant Rv3864 ko or
Rv3867 ko strains, suggesting that Rv3864, Rv3865, Rv3866,
and Rv3867 are not directly involved in the translocation of
ESAT-6 and CFP-10 (Fig. 5A). In contrast, interruption of
Rv3868, Rv3869, Rv3870, or Rv3871 resulted in the loss of
ESAT-6 and CFP-10 secretion despite normal expression of these
antigens. These results were further confirmed by M. microti::RD1-
2F9Rv3868-69 (AscI), and M. microti::NheI-Rv3869-79 (Fig.
4), both lacking complete Rv3868 and/or Rv3869 genes. Like
FIG. 5. Secretion analysis. In vitro expression and secretion of ESX-1 antigens from recombinant M. microti, BCG, and M. tuberculosis
H37RvRD1 complemented with integrating cosmids that were mutated in selected RD1 genes was examined. Total protein concentrations were
determined by using Bio-Rad protein assay, and 20-g samples were subjected to SDS-PAGE. PPE68, CFP-10, and ESAT-6 correspond to
products encoded by ppe68 (Rv3873), esxB (Rv3874), and esxA (Rv3875) genes, respectively. (A) CM, whole-cell extract containing cytosolic and
membrane fractions; S, supernatant. Detection was carried out by using monoclonal anti-ESAT-6, polyclonal anti-CFP-10, and polyclonal
anti-PPE68 antibodies. (B) Analysis of recombinant M. tuberculosis pe35 ko and control strains: (a) secretion analysis with same antibodies as
described for panel A; (b) PCR control amplification obtained with primers for genes pe35 to Rv3877 for pe35 ko and RD1-2F9 M. tuberculosis
H37RvRD1 strains; (c) hybridization signals obtained with radiolabeled cDNA from M. tuberculosis H37RvRD1::RD1-2F9 and pe35 ko mutant
using a focused mini-array containing PCR products from selected genes of the RD1 region spotted on nylon membranes in duplicates.
(C) Secretion analysis of recombinant M. tuberculosis strains lacking part of the ppe68 (Rv3873) gene or the described promoter region of esxB/A
(rv3874-75) (4), with the same antibodies as described for panel A.
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the Rv3868 ko, and Rv3869 ko strains, these strains expressed
ESAT-6 and CFP-10 but were unable to secrete the two anti-
gens into the culture supernatant (data not shown). These
results indicate that Rv3868 and Rv3869, in addition to the
previously identified Rv3870 and Rv3871 (23, 35, 40), are in-
deed important for efficient export of ESAT-6 and CFP-10.
When a pe35 ko pRD1-2F9 construct (Fig. 4) was integrated
into M. tuberculosis H37RvRD1, ESAT-6 and CFP-10 pro-
teins were not detected in either whole-cell lysate or the su-
pernatant (pe35 ko, Fig.5Ba). These results were confirmed
independently by the observation that a pe35 ko mutant of
M. tuberculosis MT103, isolated by signature-tagged mutagen-
esis, also lacked CFP-10 and ESAT-6 completely and PPE68
(Fig.5Ba). To investigate whether loss of PE35 acted at the
transcriptional level, focused miniarray analysis of gene expres-
sion was performed with the appropriate cDNA probes. This
revealed that esxB/A genes were not transcribed in the PE35
mutant (Fig.5Bc). To evaluate whether the lack of ESAT-6
expression in the pe35 ko mutants was due to polarity from the
transposon insertion, the previously described promoter region
[prom(esxB/A)] (4) or a region even farther upstream located
in the 3 end of gene ppe68 (ppe68) was deleted from pRD1-
2F9 (Fig. 4). For the construct that was missing the described
promoter region, only trace amounts of ESAT-6 and CFP-10
were found, whereas the recombinant strain lacking the seg-
ment further upstream of the described promoter (ppe68) did
produce large amounts of ESAT-6 and CFP-10 (Fig. 5C).
From these experiments we concluded that CFP-10 and
ESAT-6 are indeed expressed from their own promoter up-
stream of esxB and should not be subject to downstream effects
of the transposon insertion in pe35. Together, these findings
suggest that PE35 plays a role in the regulation of esxB/A
expression, a hypothesis, which can now be tackled by more
in-depth studies.
Regarding esxB (Rv3874), an in-frame deletion of 46 codons
resulted in absence of CFP-10 from recombinant BCG (Fig. 5A)
or M. microti. More surprisingly, in this strain ESAT-6 was not
detected either. Three recombinant BCG::RD1 strains with in-
frame deletions, lacking the complete esxA (Rv3875) gene
(esxA), or 20 to 22 codons from either end of esxA (esxA3-24
and esxA76-95), showed similar phenotypes. Neither ESAT-6
nor CFP-10 were detectable in the cell lysates and supernatants of
these strains, suggesting that their expression is tightly linked to
each other.
Concerning Rv3876, located downstream of esxA, two different
recombinants were constructed: an insertion mutant (Rv3876 ko)
and an in-frame deletion mutant lacking two-thirds of the gene
(Rv3876 [Fig. 4]). For both recombinant BCG strains, ESAT-6
and CFP-10 were detected in the culture supernatant, implying
that Rv3876 may not be directly involved in the secretion of the
two antigens (Fig. 5A). Furthermore, secretion of CFP-10 was
reduced when Rv3877 was interrupted (data not shown). The
remaining two RD1-associated genes absent from BCG, Rv3878
and Rv3879, are not necessary for the export of the antigens since
recombinant strains harboring pRD1-2F9 with the segment from
Rv3878 to Rv3881 deleted efficiently secreted the antigens, con-
firming previous results with a clinical isolate naturally deleted for
these genes (Fig. 5A) (35).
Export of whole ESAT-6 is required to elicit ESAT-6-specific
T-cell immune responses. To substantiate in vitro secretion re-
sults, splenocytes from C57BL/6 mice immunized with various
recombinant strains were tested for their capacity to mount
ESAT-6- and CFP-10-specific T-cell responses. Inoculation with
Rv3868 ko, Rv3869 ko, Rv3870 ko, Rv3871 ko, esxB, esxA,
esxA3-24, esxA76-95, or rv3877 ko strains did not induce
ESAT-6 specific IFN- production by splenocytes (Table 1).
In contrast, Rv3860-64, Rv3860-66, Rv3864 ko, Rv3867 ko,
and Rv3876 ko strains elicited ESAT-6-specific IFN- re-
sponses comparable to those induced by BCG::RD1 and M.
microti::RD1, emphasizing the accuracy of the in vitro secre-
tion results. In summary, an ESAT-6-specific T-cell response
was obtained for the recombinant strains that were not only
expressing ESAT-6 and CFP-10 but also secreting the two
antigens. As such, the IFN- production is a reliable readout
system to evaluate whether or not ESAT-6 was secreted by the
various recombinant strains.
However, this finding was only true for recombinant strains,
which carried a full-length esxA gene. Mice infected with
BCG::RD1 lacking 12 residues of the extreme C terminus of
ESAT-6 (esxA84-95) (6) did not develop ESAT-6-specific
immune responses in spite of normal secretion of the truncated
ESAT-6 molecules (Table 1). It is noteworthy that the T-cell
epitope (CD4), which is located within the N-terminal region
of ESAT-6, is not absent in this strain.
Pathogenicity of BCG::RD1 andM. microti::RD1 strains cor-
relates with ESAT-6 immunogenicity. Since the SCID mouse
model provides a relatively fast screen for virulence, the above-
described BCG::RD1 and M. microti::RD1 mutants were as-
sayed for their virulence in vivo as outlined previously (8, 34).
We tested previously constructed recombinant BCG strains
(35) that contained only partial sections of the RD1 region
(pAP34, pAP35, and pI106) and do not efficiently secrete
ESAT-6 and CFP-10 proteins, and we found no increase in
bacterial load relative to the BCG::pYUB412 vector control
strain (Table 1).
The same attenuated phenotype was observed for M. microti
ko strains that were impaired in the export of ESAT-6 due to
interruption of a gene whose encoded protein is predicted to
be part of the ESX-1 secretion system (e.g., Rv3868, Rv3869,
Rv3870, and Rv3871) (Table 1). On the other hand, mice that
were infected with recombinant M. microti strains inactivated
in genes not involved in ESAT-6 secretion (Rv3860-64, Rv3864
ko, Rv3867 ko, ppe68 ko, Rv3876, or Rv3876 ko) showed
severe splenomegaly and high bacterial counts in their lungs
and spleens similar to those of M. microti::RD1 controls. How-
ever, one exception was found for M. microti Rv3860-66
strain, which secreted ESAT-6 and retained antigen-specific
T-cell immunogenicity (Fig. 5A and Table 1) without showing
enhanced in vivo growth in SCID mice.
As with M. microti::RD1 constructs, a correlation between the
capacity to induce immune responses to ESAT-6 and CFP-10 and
enhanced in vivo growth was obtained for BCG::RD1 strains,
which were inactivated for genes in the region of pe35 to Rv3877.
Indeed, insertions or deletions in genes encoding PE35, CFP-10
(EsxB, Rv3874), and ESAT-6 (EsxA, Rv3875) resulted in an
attenuated phenotype. Again, disruption of ppe68 or rv3876
within recombinant BCG::RD1 strains led to enhanced in vivo
growth in SCID mice as seen for M. microti. Interestingly, a BCG
strain carrying a truncated copy of ppe68 was even more virulent
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than BCG::RD1, since mice died within 3 weeks postinfection,
before the end of the experiment (Table 1).
DISCUSSION
The goal of this study was to define the gene set required for
production of a functional ESX-1 system by using biologically
relevant in vitro and in vivo screens. Unlike bacterial type III
or IV secretion processes, ESAT-6 secretion occurs in in vitro
grown cultures and does not seem to require host cell target
interaction for translocation of the secreted proteins. Accord-
ing to their relevance in this process, the analyzed genes can be
grouped into four classes (Table 2).
Inactivation of genes from the first class led to absence of
ESAT-6 and CFP-10 from cell lysates of the tested recombi-
nants. Whereas our data confirmed what was previously pub-
lished for esxA and esxB (14, 23), to our knowledge this is the
first report describing the importance of gene pe35 (Rv3872)
for expression of CFP-10 and ESAT-6. It is encouraging that
the two pe35 ko mutants, which were obtained by independent
approaches, both yielded the same results concerning esxB/A
expression, and this result opens new perspectives for studying
the regulation of ESX-1 genes.
Interruption or deletion of genes from the second group
abolished ESAT-6 export but not its expression. Some of the
genes from this group were proposed previously as being in-
volved in secretion of ESAT-6 (Rv3877, Rv3871, and Rv3870)
(23, 35, 40), whereas others (Rv3868 and Rv3869) are reported
here for the first time in the M. tuberculosis complex. The
involved genes encode for Rv3868, a chaperone-like protein
with an ATP binding site; Rv3869, Rv3870, and Rv3877, three
TABLE 1. Comparison of ESX-1-specific T-cell immunity and virulence obtained with M. microti




Virulence in SCID mice
(ratio of CFU at day 30
relative to that at day 0) A/V phenotype
ESAT-6:1-20 rESAT-6 rCFP-10 Lungs Spleen
M. microti
pYUB412    4 2 A,  control
pRD1-2F9 16 20 17 100 80 V,  control
Rv3860-64 22 17 16 94 26 V
Rv3860-66 12 12 10 14 2 A
Rv3864 ko 10 14 10 19 42 V
Rv3867 ko 19 14 17 2,133 12 V
Rv3868 ko    5 1.3 A
Rv3869 ko    13 2 A
Rv3870 ko    1.2 3.2 A
Rv3871 ko    23 2 A
ppe68 ko 18 12 8 288 16.2 V
esxB    ND ND A*
esxA    ND ND A*
esxA3-24    ND ND
Rv3876 ko  5 6 39.5 79.6 V
Rv3876  4 5 644 47 V
Rv3869-79    4 2.9 A
BCG
pYUB412    15 86 A,  control
pRD1-2F9 22 22 21 15,066 1,095 V,  control
pAP34 * * * 3 8 A
pAP35 * * * 1 11 A
pI106 * * * 34 2 A
ppe68 ko 16 18 14 59,627 210 V
esxB    ND ND A*
esxA3-24    ND ND
esxA    ND ND A*
esxA76-95    ND ND
esxA84-95    17 18 A
Rv3876 ko 18 19 10 6,247 184 V
Rv3876 7 9 6 533 180 V
Rv3877 ko    ND ND A*
Rv3878-81 20 23 22 ND ND V*
Rv3869-79 20 19 10 3,840 702 V
a The concentration of IFN- in the culture supernatants of splenocytes that were stimulated with ESAT-6:1-20 peptide, recombinant ESAT-6 protein (rESAT-6),
or recombinant CFP-10 protein (rCFP-10) is given. In all cases, efficient immunization and specificity of IFN- secretion by splenocytes was validated with purified
protein derivative and MalE:100-114 peptide as positive and negative controls, respectively. The results are from at least two independent experiments with three mice
and are expressed as mean values of duplicate culture wells. The standard deviations are within 10%. The “” symbol indicates that the signal was below the detection
limit (1 ng/ml). The ratio of CFU at day 30 relative to the initial dose recovered from the lungs and spleen of SCID mice after intravenous infection with 106 CFU
is also given. Each value is the mean of three mice. Note that CFU ratios from the lungs after intravenous infection have been observed to be subject to
interexperimental variation and should be read relative to the positive and negative controls. A, Attenuated phenotype similar to pYUB412-complemented negative
controls; V, virulent phenotype, similar to pRD1-2F9-complemented positive controls. In addition, animals infected with strains classified as “V” showed bad health
conditions with respect to the appearance of their fur, their reactiveness, and splenomegaly at the time of sacrifice relative to animals infected with strains classified
as “A.” An asterisk indicates that an immunogenicity a virulence evaluation in the M. tuberculosis complex was reported previously (23, 26, 35, 40). ND, not determined.
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putative membrane proteins containing 1-, 3-, or 11-transmem-
brane domains; and Rv3871 containing an ATP-binding site.
The last four proteins may form a membrane-bound complex
that is involved in the translocation of ESAT-6 and CFP-10. It
is likely that this transport is powered by ATP hydrolysis. For
constructs with inactivated genes from class 2, the inability to
secrete ESAT-6–CFP-10 resulted in a lack of antigen specific
immunogenicity and led to an attenuated phenotype, which is
similar to what was observed for genes of class 1. Although the
orthologue of Rv3868 was reported to be part of the RD1-en-
coded locus that regulates DNA transfer in Mycobacterium smeg-
matis (17), in another study Rv3868 was not found to be impli-
cated in the secretion of the M. smegmatis ESAT-6 and CFP-10
orthologues (15). In the phylogenetically more closely related
Mycobacterium marinum, Rv3868 was reported to be involved in
the secretion of ESAT-6 and CFP-10 orthologues (21).
In contrast, inactivation of genes from the third class com-
prising Rv3864, Rv3867, ppe68 (Rv3873), Rv3876, Rv3878, and
Rv3879 did not abolish ESAT-6 secretion, ESAT-6-specific
immunogenicity, and enhanced virulence. Truncation or inac-
tivation of PPE68 even led to a moderate increase of secreted
ESAT-6, suggesting that this protein could possibly act as a
gating protein that regulates the release of ESX-1 antigens.
For gene Rv3876, Guinn et al. reported that the gene product
is needed for secretion of ESAT-6 (23). We found that an
in-frame deletion of more than half of Rv3876 did not affect
the secretion and the enhanced in vivo growth phenotype of
the complemented BCG strain, suggesting that the results ob-
served by Guinn et al. may have been caused by polar effects of
the transposon insertion on gene Rv3877, which is required for
secretion.
The fourth group is constituted by Rv3865/Rv3866, whose
deletion led to the attenuation of the recombinant strain, in
spite of strong ESAT-6 secretion and generation of specific
T-cell responses. In a recent study, Rv3865 was found to be
abundant in culture medium of a clinical M. tuberculosis isolate
belonging to the Beijing family (1), and Rv3866 has recently
been proposed to be specifically involved in the anaerobic
growth of M. tuberculosis (41). For M. smegmatis and M. ma-
rinum (15, 21), the Rv3866 orthologues were described as
being implicated in the secretion of ESAT-6 and CFP-10
orthologues, whereas in M. leprae the Rv3865 orthologue is
decayed and Rv3866 is a pseudogene (30). Further studies are
needed to clarify the roles of Rv3865 and Rv3866 in M. tuber-
culosis, which may represent a new class of important RD1-
associated virulence factors, independent of ESAT-6 secretion
or alternatively, possibly involved in stabilizing or modifying
the ESAT-6–CFP-10 complex. Although some common traits
can be found for ESX-1-related data from various mycobacte-
rial species, it seems that there exist several specific differences
for the ESX-1 system in the various mycobacteria, which may
reflect the adaptation processes to the requirements of each
species. In addition, some proteins encoded elsewhere in the
genome may also play a role (20).
As shown in detail in Table 1, one of the main conclusions
that can be drawn from the results with the first three classes of
mutants are that in general export of ESAT-6 correlates with
antigen-specific induction of IFN- immune recognition and
that RD1-induced virulence requires a functional ESX-1 se-
cretion apparatus. This suggests that ESAT-6 is not processed
by the antigen-presenting cells of the mouse, nor does it fulfill
its biological role in the infection process if it remains inside
the cytosol of the bacterium. The need for an active process
probably involving interaction with host cell proteins is further
substantiated by the observation that a recombinant BCG
strain secreting truncated ESAT-6 (esxA84-95) (6) was im-
paired to induce ESAT-6 specific IFN- production in the
mouse (Table 1). It seems plausible that the C terminus of
ESAT-6 may be involved in such an interaction. These obser-
vations are consistent with a major premise of mycobacterial
vaccinology, which states that vaccination with BCG only in-
duces efficient protection when live BCG is administered and
not if heat-killed cells are used (38), suggesting that active
secretion of a wide range of mycobacterial antigens is a pre-
requisite for generation of a protective immune response.
It was shown that in immunocompetent mice increased vir-
ulence of ESX-1 complemented strains may be compensated
for by a strong, RD1-encoded antigen-specific activation of
cells involved in innate or adaptive immunity (29). In the
present study we have substantiated this observation by intra-
venous infection of mice impaired in IFN- or TNF- signaling
pathways, confirming the important role of these cytokines in
the normal control of the infection. However, it is still not clear
why, in the absence of T-cell-mediated immune responses,
RD1-complemented bacteria tend to show enhanced in vivo
growth characteristics. The finding that bone-marrow-derived
macrophages take up ESAT-6-secreting recombinant strains
more efficiently than ESX-1-negative control strains may in
part be responsible for this effect. However, further studies
involving a set of defined ESX-1 mutant strains are needed to
identify the ESX-1 effector molecules and the putative macro-
phage receptor responsible for this phenomenon.






1 pe35 (Rv3872), esxB (Rv3874), and esxA (Rv3875) No No No No
2 Rv3868, Rv3869, Rv3870, Rv3871, and Rv3877 Yes No No No
3 Rv3864, Rv3867, ppe68 (Rv3873), Rv3876, and
Rv3878/Rv3879
Yes Yes Yes Yes
4 Rv3865/Rv3866 Yes Yes Yes No
a esxB encodes for CFP-10, and esxA encodes for ESAT-6. The expression and secretion of CFP-10 and ESAT-6 are monitored by Western blot analysis of
mycobacterial whole-cell extract and culture filtrates. The ESAT-6-specific immune response corresponds to the generation of IFN- after in vitro stimulation by
ESAT-6 of splenocytes from immunized mice. RD1-mediated virulence is determined by numbering the bacterial load 4 weeks after infection of SCID mice.
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